In a setback, Global Blood Therapeutics scraps IPF program as lead drug flounders in proof-of-concept trials
It’s all or nothing for Global Blood Therapeutics’ clinical trial program for sickle cell disease.
The South San Francisco-based biotech announced this morning that it is scrapping an ambitious early-stage effort to develop their lead drug GBT440 as a therapy for hypoxemia — low levels of oxygen in the blood of patients suffering from idiopathic pulmonary fibrosis. That leaves sickle cell disease as the sole indication now being studied in the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.